Should I buy Medtronic (MDT) stock or is it too late?

Medtronic · Health Care · price $93

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Stifel — 68% of its targets hit on this sector (304 calls tested). It aims for $95 (+2.1 %), call made on September 3, 2026, maturing on September 3, 2027 (41 d ago).

The 10 reliable analysts $102+9.7 %

The 6 other firms $102+9.7 %

How to read it: the 10 reliable firms are not filtered by optimism — 10 aim above the price, 0 below, hence their $102 median. “The 6 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Medtronic

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
B of A Securities	100 %	+17.3 %	6	$110 +18%
JP Morgan	100 %	+16.0 %	7	$100 +8%
BTIG	86 %	+15.7 %	7	$99 +6%
Barclays	78 %	+12.6 %	9	$95 +2%
Citigroup	65 %	+8.3 %	26	$110 +18%
UBS	45 %	+5.7 %	11	$110 +18%
Evercore ISI Group	80 %	+4.3 %	5	$105 +13%
Mizuho	57 %	+4.3 %	7	$100 +8%

In short — Should you invest in Medtronic? Is it too late, still worth it? Analysts are fairly positive (69% buy, median target $102, i.e. +10%), and the most reliable on MDT targets even higher. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

69% of analysts rate it a buy (Buy consensus, 16 ratings) — a sign of market conviction.
Median price target $102, i.e. +10% from the current price ($93).
The most reliable firm on MDT, B of A Securities (100% hit rate, 6 scored calls), targets $110 (call made on September 2, 2026, maturing on September 2, 2027) (+18%) in its most recent call.
6 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.
Pays a dividend (3.6% yield), raised for 22 years — regular income on top of potential upside.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 16 ratings, 5 are neutral.
A 12-month target is not a guaranteed path: the price can fall in the meantime.

The analyst consensus on MDT

Median target $102 (+10%) · 16 ratings · Buy consensus

Strong Buy00%

Buy1169%

Hold531%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Medtronic now?

We won't decide for you. The facts: 69% of analysts rate it a buy, median target $102 (+10%), and B of A Securities (most reliable on MDT, 100%) targets $110. Weigh that against valuation (P/E ~23). This is not personalized advice.

Is it too late to invest in Medtronic?

Not according to analysts: the median target ($102) is still +10% above the current price ($93) (most reliable on MDT: B of A Securities, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Medtronic still worth investing in?

It depends on the gap between the price ($93) and its estimated value: analysts target $102 on median (+10%), with 69% buys (most reliable on MDT: B of A Securities, 100%). Cross-check with their real reliability on MDT and the cautions above. Information, not advice.

What's the main risk in buying MDT?

The consensus is not unanimous: of 16 ratings, 5 are neutral.

→ Go deeper: the full Medtronic profile (consensus, analyst reliability, price target, performance).